MDX 214

Drug Profile

MDX 214

Alternative Names: Anti-EGFr/CD89 antibody; MDX-214

Latest Information Update: 03 May 2007

Price : $50

At a glance

  • Originator Medarex
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Cancer

Most Recent Events

  • 03 May 2007 Discontinued - Phase-I/II for Cancer in USA (unspecified route)
  • 05 Aug 2005 This compound is still in active development - (BIO-2005)
  • 23 Apr 2004 Phase-I/II clinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top